VTYX - Ventyx Biosciences, Inc.
14
0.020 0.143%
Share volume: 5,448,870
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$13.98
0.02
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | |
| Report Date | 05-09-2024 | 08-08-2024 | 11-07-2024 | 02-27-2025 | 05-08-2025 | 11-06-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | ||||
| Operating expenses | 41.768 M | 35.712 M | 38.552 M | 32.418 M | 30.097 M | 24.874 M | |
| Selling general and admin | 8.021 M | 7.907 M | 7.923 M | 7.597 M | 7.199 M | 7.168 M | |
| Research and development | 33.747 M | 27.805 M | 30.629 M | 24.821 M | 22.898 M | 17.706 M | |
| Total expenses | 41.768 M | 35.712 M | 38.552 M | 32.418 M | 30.097 M | 24.874 M | |
| -14.50% | 7.95% | -15.91% | -7.16% | -17.35% | |||
| Operating income | -41.768 M | -35.712 M | -38.552 M | -32.418 M | -30.097 M | -24.874 M | |
| Ebit | -41.799 M | -35.733 M | -38.599 M | -32.418 M | -30.106 M | -24.884 M | |
| Pretax income | -38.572 M | -31.950 M | -35.249 M | -29.351 M | -27.440 M | -22.829 M | |
| -17.17% | 10.33% | -16.73% | -6.51% | -16.80% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -38.572 M | -31.950 M | -35.249 M | -29.351 M | -27.440 M | -22.829 M | |
| 17.17% | -10.33% | 16.73% | 6.51% | 16.80% |